Previously, the company developed and tested a bovine form of AP in three phase II trials in patients with sepsis, AKI and UC.AM-Pharma has since developed and manufactured a proprietary and fully human recombinant form of AP, known as recAP.
Timeline
September 13, 2011
AM Pharma raises a $39,843,400 series D round from Shire, IDInvest Partners, Ysios Capital, BB Biotech Ventures, Inventages Venture Capital Investment Inc., Kurma Life Science Partners, Abbott Laboratories and Forbion Capital Partners.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
References
AM Pharma
Is a
Company attributes
Industry
Location
Total funding amount (USD)
172,843,400
